Vir Biotechnology, Inc.

NASDAQ:VIR

Biotechnology

Healthcare
$9.15 -2.63%

-$0.25 today

Market cap
$1.57B
Beta
1.64
P/E (TTM)
-3.0
EPS (TTM)
-$3.00
52W Low $4.16High $11.66

Volume 2.15M

Average 1.76M

VIR Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Vir Biotechnology, Inc.NASDAQ: VIR

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $108.92M fell 8.2% year over year, ahead of the -15.0% change in trailing-twelve-month research & development. Sequentially, it rose 23.3% from the prior quarter. Over 3 fiscal years it compounded at -3.0% a year.

Context

  • Research & development amounted to 631.3% of revenue in FY2025, down 51.3 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -8.2% holds above the trailing-twelve-month pace of -15.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$108.92M+23.3% QoQ
Last fiscal yearDec 2025
$432.8M-14.6% YoY
LTMMar 2026
$446.24M-15.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.2%——
1 year-14.6%——
3-year CAGR-3.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
432.8M USD
Year-over-year change
-14.6%
4-year CAGR
-0.9%

Research & Development vs competitors

How VIR compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -15.0% is the 7th highest of 10, against a peer median of -0.6%.
  • Research & development amounts to 681.3% of revenue for VIR, versus a peer median of 70.2%.
VIR Competitors
Research & Development for VIR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRNAModerna, Inc.LTM Sep 2026$2.66B USD-23.6%-1.7%105.3%
BNTXBioNTech SELTM Jun 2026€2.18B EUR-0.6%+9.6%82.6%
VIRVir Biotechnology, Inc.LTM Mar 2026$446.24M USD-15.0%-3.0%681.3%
NVAXNovavax, Inc.LTM Mar 2026$345.36M USD-10.9%-35.2%57.9%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$197.76M USD+15.5%-13.1%21.0%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$159.57M USD+37.4%+18.6%—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$91.32M USD-20.8%-13.4%131.9%
VALNValneva SELTM Mar 2026€85.57M EUR+12.6%-6.7%54.7%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$64.86M USD+10.1%-2.5%91.2%
ABUSArbutus Biopharma CorporationLTM Mar 2026$20.4M USD-57.1%-33.1%10.7%
Peer median (excluding VIR) —-0.6%-6.7%70.2%

Competitors are the stored peer set for VIR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.1B1.62B86.18M74.21M68.56M
Cost of Revenue513.87M620.97M572.83M478.65M11.71M
Gross Profit581.54M994.83M(486.65M)(404.44M)56.85M
Gross Margin53.1%61.6%-564.7%-545.0%82.9%
Research & Development448.01M474.65M579.72M506.5M432.8M
Selling, General & Admin000092.07M
Operating Expenses160.79M161.76M197.66M182.73M524.87M
Depreciation & Amortization5.81M6.78M19.45M14.56M11.68M
EBITDA555.61M761.06M(641.64M)(508.91M)(426.09M)
EBITDA Margin50.7%47.1%-744.5%-685.8%-621.5%
Operating Income420.75M833.07M(684.31M)(587.17M)(468.02M)
Operating Margin38.4%51.6%-794.0%-791.3%-682.7%
Interest Income439K28.09M86.99M71.81M40.24M
Interest Expense00000
Other Income / Expenses129.05M(78.79M)56.11M64.06M30.25M
Income Before Tax549.8M754.28M(628.19M)(523.11M)(437.77M)
Pre-Tax Margin50.2%46.7%-728.9%-704.9%-638.6%
Income Tax Expense21.22M238.44M(13.08M)(1.15M)217K
Net Income528.58M515.84M(615.06M)(521.96M)(437.99M)
Net Margin48.3%31.9%-713.7%-703.4%-638.9%
EPS (Basic)4.073.89(4.59)(3.83)(3.16)
EPS (Diluted)3.963.83(4.59)(3.83)(3.16)
Weighted Avg Shares129.88M132.61M134.13M136.25M138.52M
Weighted Avg Shares (Diluted)133.44M134.81M134.13M136.25M138.52M

Vir Biotechnology, Inc.

NASDAQ:VIR

Intrinsic Alpha fair value

Locked

Current Price

$9.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.